Gheuens Sarah 4

4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 23, 2026

AI-generated summary of this filing

Updated Jun 23, 2026

Agios (AGIO) CMO Sarah Gheuens Receives 3,000 Performance Stock Units

What Happened

Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals (AGIO), had 3,000 performance-based equity units recorded on June 18, 2026. The Form 4 shows a conversion/exercise of 3,000 derivative units and an acquisition/grant of 3,000 derivative units at $0.00 — no cash changed hands and the reported value is $0.
This is an award tied to milestone achievement (not an open-market buy or sale). The underlying shares remain contingent and will only vest on December 31, 2027 subject to continued service.

Key Details

Transaction date: June 18, 2026; Form 4 filed June 23, 2026.
Reported amounts/prices: 3,000 units exercised/converted (M) @ $0.00 (disposed) and 3,000 units granted/acquired (A) @ $0.00; total reported consideration $0.
Shares owned after transaction: not specified in the filing.
Footnotes of note:
- F1: Each performance stock unit (PSU) is a contingent right to one share.
- F2: PSUs were originally granted March 1, 2025; the specified research milestone was determined met on June 18, 2026. Shares related to that milestone will vest on December 31, 2027 subject to continued service.
- F3: Restricted stock unit definition (standard disclosure).
Filing timeliness: Form shows filing date; the filing does not state that it was late.

Context

These entries reflect milestone-based equity compensation (PSUs) rather than a cash purchase or immediate share sale. The units are contingent and will only convert into actual shares if vesting conditions (including continued service through 12/31/2027) are met.
Such awards are common executive compensation and do not directly indicate immediate insider buying or selling in the market.

Form 4

Period: 2026-06-18

Chief Medical Officer

Transactions

Exercise/Conversion
Performance share units
[F1][F2]
2026-06-18−3,000→ 9,000 total
→ Common stock (3,000 underlying)
Award
Restricted stock units
[F3][F2]
2026-06-18+3,000→ 3,000 total
→ Common stock (3,000 underlying)

Footnotes (3)

[F1]Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
[F2]Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
[F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Signature

/s/ William Cook, as attorney-in-fact for Sarah Gheuens|2026-06-23

1 file